Glaucoma: Seven-Market Drug Forecast and Market Analysis - Update
Summary
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Glaucoma market through 2033.
According to GlobalData, 2023 sales of glaucoma therapeutics across the 7MM are estimated to be $2.1 billion. The market is projected to grow at a compound annual growth rate (CAGR) of 2.1%, reaching approximately $2.5 billion by 2033.
The major drivers of glaucoma market growth over the forecast period are -
- A projected increase in the prevalence of glaucoma throughout the 7MM resulting from an aging population.
- The launches of six pipeline agents in the US and Japan.
- The anticipated launches of new products are expected to address unmet needs in the treatment of glaucoma.
- Several products are due to lose exclusivity within the forecast period, and the subsequent generic erosion represents a significant impediment to growth.
- Poor adherence to therapy will continue to stymie the sales of topical glaucoma therapies throughout the forecast period.
- The crowded and highly genericized nature of the glaucoma market represents significant competition for new therapies.
- Overview of glaucoma, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized glaucoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the glaucoma therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for glaucoma treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global glaucoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM glaucoma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM glaucoma therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- About GlobalData
- 1 Glaucoma: Executive Summary
- 1.1 The glaucoma market will increase between 2023 and 2033.
- 1.2 The development of drugs with novel MOAs or routes of administration marks a shift in glaucoma corporate strategy.
- 1.3 Unmet needs remain for glaucoma, particularly improving patient compliance.
- 1.4 Late-stage pipeline drugs entering the glaucoma market are poised to drive growth.
- 1.5 What do physicians think?
- 2 Introduction
- 2.1 Catalyst
- 2.2 Related reports
- 2.3 Upcoming reports
- 3 Disease Overview
- 3.1 Etiology and pathophysiology
- 3.1.1 Overview
- 3.1.2 Etiology
- 3.1.3 NTG
- 3.1.4 Pathophysiology
- 3.2 Classification or staging systems
- 4 Epidemiology
- 4.1 Disease background
- 4.2 Risk factors and comorbidities.
- 4.3 Global and historical trends
- 4.4 7MM forecast methodology
- 4.4.1 Sources
- 4.4.2 Forecast assumptions and methods
- 4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of POAG (excluding NTG)
- 4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of NTG.
- 4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of PACG
- 4.4.6 Forecast assumptions and methods: diagnosed incident cases of acute PACG.
- 4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of secondary glaucoma.
- 4.5 Epidemiological forecast for glaucoma (2023-33)
- 4.5.1 Diagnosed prevalent cases of POAG (excluding NTG)
- 4.5.2 Age-specific diagnosed prevalent cases of POAG (excluding NTG)
- 4.5.3 Sex-specific diagnosed prevalent cases of POAG (excluding NTG)
- 4.5.4 Diagnosed prevalent cases of NTG
- 4.5.5 Diagnosed prevalent cases of PACG.
- 4.5.6 Age-specific diagnosed prevalent cases of PACG
- 4.5.7 Sex-specific diagnosed prevalent cases of PACG
- 4.5.8 Diagnosed prevalent cases acute and chronic PACG
- 4.5.9 Diagnosed incident cases of acute PACG
- 4.5.10 Diagnosed incident cases of secondary glaucoma
- 4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 COVID-19 impact.
- 4.6.3 Limitations of the analysis
- 4.6.4 Strengths of the analysis
- 5 Disease Management
- 5.1 Diagnosis overview
- 5.1.1 Ophthalmoscopy
- 5.1.2 Tonometry
- 5.1.3 Perimetry
- 5.1.4 Pachymetry
- 5.1.5 Gonioscopy
- 5.2 Treatment overview
- 5.2.1 Treatment guidelines
- 5.3 KOL insights on disease management
- 6 Current Treatment Options
- 6.1 Overview
- 7 Unmet Needs and Opportunity Assessment
- 7.1 Overview
- 7.2 Improved patient compliance
- 7.3 Treatments with better IOP lowering-ability
- 7.4 Novel drug delivery systems
- 7.5 Neuroprotective drugs
- 7.6 Improved diagnosis and monitoring
- 8 R&D Strategies
- 8.1 Overview
- 8.1.1 New IOP-lowering drugs
- 8.1.2 Implants in glaucoma
- 8.2 Clinical trials design
- 8.2.1 Clinical endpoints for glaucoma
- 8.2.2 Inclusion and exclusion criteria
- 9 Pipeline Assessment
- 9.1 Overview
- 9.2 Promising drugs in clinical development
- 10 Pipeline Valuation Analysis
- 10.1 Overview
- 10.2 Competitive assessment
- 11 Current and Future Players
- 11.1 Overview
- 11.2 Deal-making trends
- 12 Market Outlook
- 12.1 Global markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global (7MM) issues
- 12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
- 12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
- 12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key events
- 12.4.3 Drivers and barriers
- 13 Appendix
- 13.1 Bibliography
- 13.2 Abbreviations
- 13.3 Methodology
- 13.3.1 Forecasting methodology
- 13.4 Primary research - KOLs interviewed for this report.
- 13.4.1 KOLs
- 13.5 Primary research - prescriber survey
- 13.6 About the authors
- 13.6.1 Analyst
- 13.6.2 Therapy Area Director
- 13.6.3 Epidemiologist
- 13.6.4 Reviewers, epidemiology
- 13.6.5 Vice President of Disease Intelligence and Epidemiology
- 13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence
- Contact Us
- List of Tables
- Table 1: Glaucoma: Key metrics in the 7MM
- Table 2: The different causes of secondary glaucoma
- Table 3: Classification of glaucoma by ICD-10 codes
- Table 4: Classification of glaucoma by primary and secondary groups
- Table 5: Classification of glaucoma by OAG and ACG sub-types
- Table 6: Risk factors and comorbidities for glaucoma
- Table 7: Diagnostic tests for glaucoma
- Table 8: Ophthalmologic imaging techniques
- Table 9: Treatment guidelines for glaucoma
- Table 10: Top 10 deals by value, 2019-24
- Table 11: Glaucoma market - global (7MM) drivers and barriers, 2023-33
- Table 12: Key events impacting sales for glaucoma in the US, 2023-33
- Table 13: Glaucoma market - drivers and barriers in the US, 2023-33
- Table 14: Key events impacting sales for glaucoma in the 5EU, 2023-33
- Table 15: Glaucoma market - drivers and barriers in the 5EU, 2023-33
- Table 16: Key events impacting sales for glaucoma in Japan, 2023-33
- Table 17: Glaucoma market - drivers and barriers in Japan, 2023-33
- Table 18: High-prescribing physicians (non-KOLs) surveyed, by country
- List of Figures
- Figure 1: Global sales forecast by country for glaucoma in 2023 and 2033
- Figure 2: Analysis of the company portfolio gap in glaucoma during the forecast period
- Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of glaucoma during the forecast period
- Figure 4: The AqH flow in OAG and ACG
- Figure 5: The AqH Cycle
- Figure 6: 7MM, diagnosed prevalence of POAG (including NTG), both sexes, %, ages ≥40 years, 2023
- Figure 7: 7MM, diagnosed prevalence of POAG (excluding NTG), both sexes, %, ages ≥40 years, 2023
- Figure 8: 7MM, diagnosed prevalence of PACG, both sexes, %, ages ≥40 years, 2023
- Figure 9: 7MM, sources used and not used to forecast the diagnosed prevalent cases of POAG (excluding NTG)
- Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of NTG
- Figure 11: 7MM, sources used to forecast the diagnosed prevalent cases of PACG
- Figure 12: 7MM, sources used to forecast the diagnosed incident cases of acute PACG
- Figure 13: 7MM, sources used to forecast the diagnosed prevalent cases of secondary glaucoma
- Figure 14: 7MM, diagnosed prevalent cases of POAG (excluding NTG), N, both sexes, ages ≥40 Years, 2023
- Figure 15: 7MM, diagnosed prevalent cases of POAG (excluding NTG) by age, N, both sexes, 2023
- Figure 16: 7MM, diagnosed prevalent cases of POAG (excluding NTG) by sex, N, ages ≥40 Years, 2023
- Figure 17: 7MM, diagnosed prevalent cases of NTG, N, both sexes, ages ≥40 years, 2023
- Figure 18: 7MM, diagnosed prevalent cases of PACG, N, both sexes, ages ≥40 years, 2023
- Figure 19: 7MM, diagnosed prevalent cases of PACG by age, N, both sexes, 2023
- Figure 20: 7MM, diagnosed prevalent cases of PACG by sex, N, both sexes, ages ≥40 Years, 2023
- Figure 21: 7MM, diagnosed prevalent cases of acute and chronic PACG, N, both sexes, ages ≥40 years, 2023
- Figure 22: 7MM, diagnosed incident cases of acute PACG, N, both sexes, ages ≥40 years, 2023
- Figure 23: 7MM, diagnosed prevalent cases of secondary glaucoma, N, both sexes, ages ≥40 years, 2023
- Figure 24: Unmet needs and opportunities in glaucoma
- Figure 25: Overview of the development pipeline in glaucoma
- Figure 26: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for glaucoma in the 7MM during the forecast period
- Figure 27: Competitive assessment of the promising pipeline agents that GlobalData expects to be licensed for glaucoma in the 7MM during the forecast period
- Figure 28: Competitive assessment of the marketed and pipeline drugs benchmarked against the SOC, latanoprost
- Figure 29: Analysis of the company portfolio gap in glaucoma during the forecast period
- Figure 30: Global (7MM) sales forecast by country for glaucoma in 2023 and 2033
- Figure 31: Sales forecast by class for glaucoma in the US in 2023 and 2033
- Figure 32: Sales forecast by class for glaucoma in the 5EU in 2023 and 2033
- Figure 33: Sales forecast by class for glaucoma in Japan in 2023 and 2033
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook